201 related articles for article (PubMed ID: 26568194)
1. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
Yamazaki J; Taby R; Jelinek J; Raynal NJ; Cesaroni M; Pierce SA; Kornblau SM; Bueso-Ramos CE; Ravandi F; Kantarjian HM; Issa JP
J Natl Cancer Inst; 2015 Nov; 108(2):. PubMed ID: 26568194
[TBL] [Abstract][Full Text] [Related]
2. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
3. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
Qu X; Othus M; Davison J; Wu Y; Yan L; Meshinchi S; Ostronoff F; Estey EH; Radich JP; Erba HP; Appelbaum FR; Fang M
Cancer; 2017 Jul; 123(13):2472-2481. PubMed ID: 28222251
[TBL] [Abstract][Full Text] [Related]
4. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
[TBL] [Abstract][Full Text] [Related]
5. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
7. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
[TBL] [Abstract][Full Text] [Related]
8. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
9. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
[TBL] [Abstract][Full Text] [Related]
10. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
11. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
[TBL] [Abstract][Full Text] [Related]
12. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
13.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
14. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
[TBL] [Abstract][Full Text] [Related]
15. Use of genome-wide DNA methylation analysis to identify prognostic CpG site markers associated with longer survival time in dogs with multicentric high-grade B-cell lymphoma.
Teoh YB; Ishizaki T; Kagawa Y; Yokoyama S; Jelinek J; Matsumoto Y; Tomiyasu H; Tsujimoto H; Takiguchi M; Yamazaki J
J Vet Intern Med; 2024; 38(1):316-325. PubMed ID: 38115210
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
17. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
[TBL] [Abstract][Full Text] [Related]
18. CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.
Hájková H; Fritz MH; Haškovec C; Schwarz J; Šálek C; Marková J; Krejčík Z; Dostálová Merkerová M; Kostečka A; Vostrý M; Fuchs O; Michalová K; Cetkovský P; Beneš V
J Hematol Oncol; 2014 Sep; 7():66. PubMed ID: 25266220
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
